IN8bio to Present at Upcoming December Investor Conferences | 2020-11-30 | Press Releases
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) — IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced that William Ho, Chief Executive Officer of IN8bio, will present at the 3 rd Annual Evercore ISI HealthCONx Conference and the JMP Securities Hematology Summit in December 2020.
|Event:||3 rd Annual Evercore ISI HealthCONx Conference|
|Date:||Tuesday, December 1 st|
|Presentation:||Track 1 panel discussion – Call my cell: Emerging Cell Therapy Platforms|
|Time:|| 1 to 1:45 p.m. EST |
|Event:||JMP Securities Hematology Summit|
|Date:||December 16 th|
|Time:||12 p.m. EST|
|Webcast:||A webcast presentation will be available at https://wsw.com/webcast/jmp47/in8.b/1660142|
IN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio’s technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit www.IN8bio.com.
Kate Rochlin, Ph.D.
Investor s :
+ 1 646.378.2936
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
firstname.lastname@example.org / email@example.com
(212) 213-0006 ext. 315 / 364